BREAKING: We're Taking the Government to Court over Palantir

Key Takeaways

• Democracy for Sale sues over secret £330m Palantir NHS contract.
• FOI request denied; government cites “safe space” for ministers.
• Good Law Project and Landmark Chambers represent the appeal.
• Case could force disclosure of how NHS data is used.

Pulse Analysis

Palantir Technologies, a data‑analytics firm founded by Peter Thiel, has secured a roughly £330 million (about $425 million) contract to build a Federated Data Platform for the National Health Service. The deal has drawn criticism from the British Medical Association and frontline doctors who warn that a company with deep ties to U.S. defence and immigration enforcement may compromise patient confidentiality. While the NHS seeks to modernise its digital infrastructure, the partnership raises questions about the governance of sensitive health records and the influence of foreign‑owned tech vendors on public services.

Democracy for Sale, an investigative outlet, filed a Freedom of Information request in March 2025 for the ministerial briefings that informed Health Secretary Wes Streeting about the Palantir project. The Department for Health and Social Care refused, citing the need for a “safe space” for policy development and to protect civil‑service neutrality. After an unsuccessful appeal, the outlet teamed with the Good Law Project and Landmark Chambers to bring the case before the Information Tribunal. Their legal strategy centers on the public‑interest test that outweighs the government’s confidentiality claim.

The outcome could set a benchmark for how UK ministries disclose contracts involving high‑risk data processing. A ruling that forces the release of the briefings would give journalists, lawmakers, and the public insight into cost structures, data‑security safeguards, and any conditional clauses tied to Palantir’s surveillance capabilities. Conversely, a decision upholding the secrecy argument may embolden future procurement of opaque tech solutions, potentially eroding trust in the NHS’s digital transformation. Stakeholders across health, privacy advocacy, and public‑sector procurement are watching the case as a litmus test for transparency in government‑tech deals.